• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利福布汀在人体中的吸收:相对生物利用度和食物效应。

Rifabutin absorption in humans: relative bioavailability and food effect.

作者信息

Narang P K, Lewis R C, Bianchine J R

机构信息

Department of Pharmacokinetics/Dynamics, Medical Research Center, Adria Laboratories, Columbus, OH 43216-6529.

出版信息

Clin Pharmacol Ther. 1992 Oct;52(4):335-41. doi: 10.1038/clpt.1992.152.

DOI:10.1038/clpt.1992.152
PMID:1330396
Abstract

The relative bioavailability of the capsule dose form (150 mg) and the effect of high-fat food were assessed in a randomized, three-way crossover trial of rifabutin in 12 healthy male volunteers. Each subject received a single 150 mg dose as a solution (treatment A, fasted) or a capsule with food (treatment B) and without food (treatment C), with a 2-week washout period. Serial plasma and urine samples were obtained for 168 and 48 hours, respectively, and rifabutin and its active metabolite, 25-O-deacetyl-rifabutin, quantitated by a validated HPLC procedure. The mean +/- SD maximum concentration for rifabutin in plasma was 238 +/- 65, 156 +/- 52, and 188 +/- 50 ng/ml, time to reach peak concentration was 2.5 +/- 0.4, 5.4 +/- 1.6, and 3.0 +/- 1.1 hours, and the area under the plasma concentration-time curve from zero to infinity [AUC(0-infinity)] was 2989 +/- 726, 2640 +/- 891, and 2516 +/- 601 ng.hr/ml for the solution and the capsule during the fed and fasted states, respectively. Percentage of dose excreted in the urine as unchanged rifabutin was 11.0% +/- 2.4%, 11.4% +/- 4.9%, and 9.1% +/- 2.1% for treatments A, B, and C, respectively. The corresponding AUC(0-infinity) values for the equiactive metabolite 25-O-deacetyl-rifabutin, were 400 +/- 184, 361 +/- 187, and 298 +/- 102 ng.hr/ml.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

在一项针对12名健康男性志愿者的利福布汀随机三交叉试验中,评估了胶囊剂型(150毫克)的相对生物利用度以及高脂食物的影响。每位受试者接受单次150毫克剂量,分别为溶液(治疗A,空腹)、进食时服用胶囊(治疗B)和空腹服用胶囊(治疗C),洗脱期为2周。分别在168小时和48小时采集系列血浆和尿液样本,通过经过验证的高效液相色谱法对利福布汀及其活性代谢物25 - O - 去乙酰基利福布汀进行定量。利福布汀在血浆中的平均±标准差最大浓度分别为238±65、156±52和188±50纳克/毫升,达到峰值浓度的时间分别为2.5±0.4、5.4±1.6和3.0±1.1小时,血浆浓度 - 时间曲线从零至无穷大的面积[AUC(0 - ∞)]在空腹状态下溶液剂型和胶囊剂型分别为2989±726、2640±891和2516±601纳克·小时/毫升。治疗A、B、C中以未改变的利福布汀形式经尿液排泄的剂量百分比分别为11.0%±2.4%、11.4%±4.9%和9.1%±2.1%。等活性代谢物25 - O - 去乙酰基利福布汀相应的AUC(0 - ∞)值分别为400±184、361±187和298±102纳克·小时/毫升。(摘要截短至250字)

相似文献

1
Rifabutin absorption in humans: relative bioavailability and food effect.利福布汀在人体中的吸收:相对生物利用度和食物效应。
Clin Pharmacol Ther. 1992 Oct;52(4):335-41. doi: 10.1038/clpt.1992.152.
2
Effect of a high-fat meal on thalidomide pharmacokinetics and the relative bioavailability of oral formulations in healthy men and women.高脂餐对沙利度胺药代动力学及口服制剂在健康男性和女性中相对生物利用度的影响。
Biopharm Drug Dispos. 2000 Jan;21(1):33-40. doi: 10.1002/1099-081x(200001)21:1<33::aid-bdd213>3.0.co;2-r.
3
The effects of food on the bioavailability of fenofibrate administered orally in healthy volunteers via sustained-release capsule.食物对健康志愿者口服非诺贝特缓释胶囊后生物利用度的影响。
Clin Pharmacokinet. 2006;45(4):425-32. doi: 10.2165/00003088-200645040-00007.
4
A new fenofibrate formulation: results of six single-dose, clinical studies of bioavailability under fed and fasting conditions.一种新的非诺贝特制剂:六项单剂量临床研究在进食和空腹条件下的生物利用度结果。
Clin Ther. 2004 Sep;26(9):1456-69. doi: 10.1016/j.clinthera.2004.09.015.
5
Relative bioavailability and effects of a high fat meal on single dose cilostazol pharmacokinetics.高脂餐对单剂量西洛他唑药代动力学的相对生物利用度及影响
Clin Pharmacokinet. 1999;37 Suppl 2:13-23. doi: 10.2165/00003088-199937002-00002.
6
Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.随机试验中口服溶液与普通片的双氯芬酸钾的药代动力学差异:进食与禁食状态的影响。
Headache. 2015 Feb;55(2):265-75. doi: 10.1111/head.12483. Epub 2014 Dec 24.
7
The relative bioavailability and fasting pharmacokinetics of three formulations of olmesartan medoxomil 20-mg capsules and tablets in healthy Chinese male volunteers: An open-label, randomized-sequence, single-dose, three-way crossover study.奥美沙坦酯 20 毫克胶囊和片剂三种制剂在健康中国男性志愿者中的相对生物利用度和空腹药代动力学:一项开放标签、随机序列、单剂量、三交叉研究。
Clin Ther. 2010 Aug;32(9):1674-80. doi: 10.1016/j.clinthera.2010.08.004.
8
Bioavailability and pharmacokinetic comparison between generic and branded azithromycin capsule: a randomized, double-blind, 2-way crossover in healthy male Thai volunteers.仿制阿奇霉素胶囊与品牌阿奇霉素胶囊的生物利用度和药代动力学比较:一项在泰国健康男性志愿者中进行的随机、双盲、双向交叉试验。
Clin Ther. 2007 Apr;29(4):703-10. doi: 10.1016/j.clinthera.2007.04.010.
9
Comparison of the Pharmacokinetics of the Phase II and Phase III Capsule Formulations of Selumetinib and the Effects of Food on Exposure: Results From Two Randomized Crossover Trials in Healthy Male Subjects.比较 Selumetinib 二期和三期胶囊制剂的药代动力学特征以及食物对暴露量的影响:两项在健康男性受试者中开展的随机交叉试验结果。
Clin Ther. 2017 Nov;39(11):2260-2275.e1. doi: 10.1016/j.clinthera.2017.08.022. Epub 2017 Oct 4.
10
A randomized, phase I, 3-way crossover study to examine the effects of food on the pharmacokinetics of single doses of 400 mg posaconazole oral suspension in healthy male Taiwanese subjects.一项随机、I 期、3 向交叉研究,旨在考察食物对健康台湾男性受试者单次口服 400mg 泊沙康唑混悬液后药物动力学的影响。
Ther Drug Monit. 2013 Apr;35(2):223-7. doi: 10.1097/FTD.0b013e3182818a56.

引用本文的文献

1
Pharmacology, Dosing, and Side Effects of Rifabutin as a Possible Therapy for Antibiotic-Resistant Infections.利福布汀作为抗生素耐药感染可能治疗方法的药理学、给药方法及副作用
Open Forum Infect Dis. 2020 Oct 15;7(11):ofaa460. doi: 10.1093/ofid/ofaa460. eCollection 2020 Nov.
2
Global access of rifabutin for the treatment of tuberculosis - why should we prioritize this?全球获取利福布丁治疗结核病的途径——我们为何要对此加以重视?
J Int AIDS Soc. 2019 Jul;22(7):e25333. doi: 10.1002/jia2.25333.
3
Effect of rifampin and rifabutin on the pharmacokinetics of lersivirine and effect of lersivirine on the pharmacokinetics of rifabutin and 25-O-desacetyl-rifabutin in healthy subjects.
利福平和利福布汀对勒韦林药代动力学的影响,以及勒韦林对利福布汀和 25-O-去乙酰利福布汀在健康受试者中药代动力学的影响。
Antimicrob Agents Chemother. 2012 Aug;56(8):4303-9. doi: 10.1128/AAC.06282-11. Epub 2012 May 29.
4
Clinical pharmacology and lesion penetrating properties of second- and third-line antituberculous agents used in the management of multidrug-resistant (MDR) and extensively-drug resistant (XDR) tuberculosis.用于耐多药(MDR)和广泛耐药(XDR)结核病管理的二线和三线抗结核药物的临床药理学及病灶穿透特性
Curr Clin Pharmacol. 2010 May;5(2):96-114. doi: 10.2174/157488410791110797.
5
Tuberculosis pharmacotherapy: strategies to optimize patient care.结核病药物治疗:优化患者护理的策略
Expert Opin Pharmacother. 2009 Feb;10(3):381-401. doi: 10.1517/14656560802694564.
6
Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials.利福霉素类抗菌药物的比较药代动力学和药效学
Clin Pharmacokinet. 2001;40(5):327-41. doi: 10.2165/00003088-200140050-00002.
7
Population pharmacokinetics of rifabutin in human immunodeficiency virus-infected patients.利福布汀在人类免疫缺陷病毒感染患者中的群体药代动力学。
Antimicrob Agents Chemother. 1998 Aug;42(8):2017-23. doi: 10.1128/AAC.42.8.2017.
8
Mycobacterium avium complex infection. Pharmacokinetic and pharmacodynamic considerations that may improve clinical outcomes.鸟分枝杆菌复合群感染。可能改善临床结局的药代动力学和药效学考量。
Clin Pharmacokinet. 1997 Feb;32(2):132-44. doi: 10.2165/00003088-199732020-00004.
9
Rifabutin is active in murine models of toxoplasmosis.利福布汀在弓形虫病的小鼠模型中具有活性。
Antimicrob Agents Chemother. 1994 Mar;38(3):570-5. doi: 10.1128/AAC.38.3.570.
10
Clinical pharmacokinetics of rifabutin.利福布汀的临床药代动力学。
Clin Pharmacokinet. 1995 Feb;28(2):115-25. doi: 10.2165/00003088-199528020-00003.